A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2013
At a glance
- Drugs ELND 002 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 01 Dec 2011 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2011 Planned end date of the extension trial (NCT01318421) is Oct 2013.